PDCD2 functions in cancer cell proliferation and predicts relapsed leukemia |
| |
| Authors: | Nora Barboza Svetlana Minakhina Daniel J. Medina Binaifer Balsara Sonya Greenwood Lien Huzzy Arnold B. Rabson Ruth Steward Dale G. Schaar |
| |
| Affiliation: | 1.University of Medicine & Dentistry of New Jersey; Robert Wood Johnson Medical School; The Cancer Institute of New Jersey; New Brunswick, NJ USA;2.Waksman Institute; Rutgers University; Piscataway, NJ USA;3.Novartis Pharmaceuticals Corporation; East Hanover, NJ USA;4.Child Health Institute of New Jersey; University of Medicine and Dentistry of New Jersey (UMDNJ); Robert Wood Johnson Medical School (RWJMS); New Brunswick, NJ USA |
| |
| Abstract: | PDCD2 is an evolutionarily conserved eukaryotic protein with unknown function. The Drosophila PDCD2 ortholog Zfrp8 has an essential function in fly hematopoiesis. Zfrp8 mutants exhibit marked lymph gland hyperplasia that results from increased proliferation of partially differentiated hemocytes, suggesting Zfrp8 may participate in cell growth. Based on the above observations we have focused on the role of PDCD2 in human cancer cell proliferation and hypothesized that aberrant PDCD2 expression may be characteristic of human malignancies. We report that PDCD2 is highly expressed in human acute leukemia cells as well as in normal hematopoietic progenitors. PDCD2 knockdown in cancer cells impairs their proliferation, but not viability relative to parental cells, supporting the notion that PDCD2 overexpression facilitates cancer cell growth. Prospective analysis of PDCD2 in acute leukemia patients indicates PDCD2 RNA expression correlates with disease status and is a significant predictor of clinical relapse. PDCD2’s role in cell proliferation and its high expression in human malignancies make it an attractive, novel potential molecular target for new anti-cancer therapies. |
| |
| Keywords: | PDCD2 acute myelogenous leukemia acute lymphoblastic leukemia cellular proliferation hematopoietic stem cells |
|
